In the present study, we first reported that targeting CXCL16 either in cancer cells using shRNA or in the microenvironment using a neutralizing antibody efficiently blocked tumor growth and angiogenesis in thyroid cancers. The gene discussed is CXCL16; the disease is thyroid gland carcinoma.